Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Namrata Saroj sold 35,370 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $6.55, for a total transaction of $231,673.50. Following the completion of the transaction, the insider owned 220,522 shares of the company's stock, valued at $1,444,419.10. This represents a 13.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ocular Therapeutix Stock Up 3.9%
Shares of NASDAQ OCUL opened at $6.85 on Tuesday. The company has a quick ratio of 13.03, a current ratio of 13.10 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average of $8.33 and a two-hundred day moving average of $9.00. Ocular Therapeutix, Inc. has a 1 year low of $6.00 and a 1 year high of $16.44.
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The company had revenue of $12.87 million during the quarter, compared to analyst estimates of $14.27 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The company's quarterly revenue was down 11.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.38) EPS. Research analysts anticipate that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.
Ocular Therapeutix News Roundup
Here are the key news stories impacting Ocular Therapeutix this week:
- Positive Sentiment: Ocular Therapeutix said it plans to submit an AXPAXLI NDA in the fourth quarter of 2026. The company reported $530.6 million in cash, which it expects to fund operations into 2028, helping ease near-term financing concerns. Article: AXPAXLI NDA plan and cash runway
- Neutral Sentiment: The company appointed Riad Sherif to its board of directors, a governance update without an immediately clear financial impact. Article: Board appointment
- Neutral Sentiment: Insider Namrata Saroj sold 35,370 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated reason and existing plan make the sale less indicative of a discretionary view on the stock. SEC insider transaction filing
- Negative Sentiment: Third-quarter adjusted loss was $0.42 per share, worse than the $0.36 loss analysts expected; revenue of $12.87 million also missed the $14.27 million consensus and fell 11.5% year over year. The earnings shortfall and weaker sales contributed to pressure on OCUL shares. Article: Ocular Therapeutix falls on third-quarter earnings miss
- Negative Sentiment: Coverage also highlighted costs associated with advancing AXPAXLI and declining DEXTENZA sales, raising questions about near-term operating performance as the company pursues its pipeline. Article: Q3 results, pipeline costs, and DEXTENZA
Analyst Ratings Changes
Several equities analysts have issued reports on OCUL shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Ocular Therapeutix in a research note on Thursday, October 15th. UBS Group began coverage on shares of Ocular Therapeutix in a research note on Sunday, October 11th. They issued a "buy" rating and a $14.00 target price for the company. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Ocular Therapeutix in a report on Tuesday, September 29th. Zacks Research upgraded shares of Ocular Therapeutix from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Finally, Chardan Capital reiterated a "buy" rating and set a $23.00 price target on shares of Ocular Therapeutix in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Ocular Therapeutix presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.33.
Read Our Latest Analysis on OCUL
Institutional Trading of Ocular Therapeutix
A number of large investors have recently made changes to their positions in OCUL. CenterBook Partners LP purchased a new position in Ocular Therapeutix in the 3rd quarter valued at about $233,000. Kraematon Investment Advisors Inc. boosted its stake in shares of Ocular Therapeutix by 6.9% during the 3rd quarter. Kraematon Investment Advisors Inc. now owns 117,517 shares of the biopharmaceutical company's stock worth $901,000 after purchasing an additional 7,550 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Ocular Therapeutix by 8.1% during the third quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 1,575 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ocular Therapeutix during the third quarter worth about $86,000. Finally, Profund Advisors LLC grew its holdings in shares of Ocular Therapeutix by 316.0% during the third quarter. Profund Advisors LLC now owns 138,128 shares of the biopharmaceutical company's stock worth $1,059,000 after buying an additional 104,927 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.
About Ocular Therapeutix
(
Get Free Report)
Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.
Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.
The company was founded in 2006 and serves the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
